scholarly journals Antiplatelet Effect of Single Antiplatelet Therapy With Prasugrel and Oral Anticoagulation After Stent Implantation in a Rabbit Arteriovenous Shunt Model

2021 ◽  
Author(s):  
Sho Torii ◽  
Tadashi Yamamoto ◽  
Norihito Nakamura ◽  
Takeshi Ijichi ◽  
Ayako Yoshikawa ◽  
...  
Keyword(s):  
Antiplatelet Therapy ◽  
Oral Anticoagulation ◽  
Stent Implantation ◽  
Arteriovenous Shunt ◽  
Antiplatelet Effect

scholarly journals Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease

Thrombosis ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Karl Mischke ◽  
Christian Knackstedt ◽  
Nikolaus Marx
Keyword(s):  
Atrial Fibrillation ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Antiplatelet Therapy ◽  
Oral Anticoagulation ◽  
Stent Implantation ◽  
Coronary Stent ◽  
Risk Scores ◽  
Coronary Stent Implantation ◽  
Artery Disease

Anticoagulation represents the mainstay of therapy for most patients with atrial fibrillation. Patients on oral anticoagulation often require concomitant antiplatelet therapy, mostly because of coronary artery disease. After coronary stent implantation, dual antiplatelet therapy is necessary. However, the combination of oral anticoagulation and antiplatelet therapy increases the bleeding risk. Risk scores such as the CHA2DS2-Vasc score and the HAS-BLED score help to identify both bleeding and stroke risk in individual patients. The guidelines of the European Society of Cardiology provide a rather detailed recommendation for patients on oral anticoagulation after coronary stent implantation. However, robust evidence is lacking for some of the recommendations, and especially for new oral anticoagulants and new antiplatelets few or no data are available. This review addresses some of the critical points of the guidelines and discusses potential advantages of new anticoagulants in patients with atrial fibrillation after stent implantation.

Sign in / Sign up

Export Citation Format

Share Document